Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

135 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Tricellulin expression in normal and neoplastic human pancreas.
Korompay A, Borka K, Lotz G, Somorácz A, Törzsök P, Erdélyi-Belle B, Kenessey I, Baranyai Z, Zsoldos F, Kupcsulik P, Bodoky G, Schaff Z, Kiss A. Korompay A, et al. Among authors: bodoky g. Histopathology. 2012 May;60(6B):E76-86. doi: 10.1111/j.1365-2559.2012.04189.x. Epub 2012 Mar 6. Histopathology. 2012. PMID: 22394074
Sorafenib with or without everolimus in patients with advanced hepatocellular carcinoma (HCC): a randomized multicenter, multinational phase II trial (SAKK 77/08 and SASL 29).
Koeberle D, Dufour JF, Demeter G, Li Q, Ribi K, Samaras P, Saletti P, Roth AD, Horber D, Buehlmann M, Wagner AD, Montemurro M, Lakatos G, Feilchenfeldt J, Peck-Radosavljevic M, Rauch D, Tschanz B, Bodoky G; Swiss Group for Clinical Cancer Research (SAKK). Koeberle D, et al. Among authors: bodoky g. Ann Oncol. 2016 May;27(5):856-61. doi: 10.1093/annonc/mdw054. Epub 2016 Feb 15. Ann Oncol. 2016. PMID: 26884590 Free article. Clinical Trial.
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, Pracht M, Yokosuka O, Rosmorduc O, Breder V, Gerolami R, Masi G, Ross PJ, Song T, Bronowicki JP, Ollivier-Hourmand I, Kudo M, Cheng AL, Llovet JM, Finn RS, LeBerre MA, Baumhauer A, Meinhardt G, Han G; RESORCE Investigators. Bruix J, et al. Among authors: bodoky g. Lancet. 2017 Jan 7;389(10064):56-66. doi: 10.1016/S0140-6736(16)32453-9. Epub 2016 Dec 6. Lancet. 2017. PMID: 27932229 Clinical Trial.
[Complex treatment of colorectal liver metastases Consensus Conference, Budapest, 5th April 2019].
Magyar Hepato-Pancreatico-Biliaris (HPB) Kutatócsoport, Semmelweis Egyetem, Általános Orvostudományi Kar, Budapest, Üllői út 78., 1082 Hungary; András C, Bartek P, Battyáni I, Bezsilla J, Bodoky G, Bogner B, Bursics A, Csőszi T, Damjanovich L, Dank M, Dankovics Z, Deák PÁ, Dede K, Doros A, Dudás I, Györke T, Hahn O, Hartmann E, Hitre E, Horváth Z, Imre M, Kalmár Nagy K, Káposztás Z, Kóbori L, Kupcsulik P, Landherr L, Lóderer Z, Mangel L, Máthé Z, Mersich T, Mezei K, Mohos E, Oláh A, Pajor P, Palkó A, Pápai Z, Papp A, Patyánik M, Petri A, Révész J, Ruzsa Á, Schlachter K, Sikorszki L, Sipőcz I, Székely E, Szijártó A, Torday L, Tóth LB, Dósa E, Harsányi L, István G, Landherr L, Lázár G, Lövey J, Schaff Z, Szűcs Á, Vereczkei A. Magyar Hepato-Pancreatico-Biliaris (HPB) Kutatócsoport, Semmelweis Egyetem, Általános Orvostudományi Kar, Budapest, Üllői út 78., 1082 Hungary, et al. Among authors: bodoky g. Orv Hetil. 2019 Sep;160(Suppl 2):2-20. doi: 10.1556/650.2019.31580. Orv Hetil. 2019. PMID: 31565959 Hungarian. No abstract available.
Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial.
Finn RS, Merle P, Granito A, Huang YH, Bodoky G, Pracht M, Yokosuka O, Rosmorduc O, Gerolami R, Caparello C, Cabrera R, Chang C, Sun W, LeBerre MA, Baumhauer A, Meinhardt G, Bruix J. Finn RS, et al. Among authors: bodoky g. J Hepatol. 2018 Aug;69(2):353-358. doi: 10.1016/j.jhep.2018.04.010. Epub 2018 Apr 26. J Hepatol. 2018. PMID: 29704513 Clinical Trial.
A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy.
Bodoky G, Timcheva C, Spigel DR, La Stella PJ, Ciuleanu TE, Pover G, Tebbutt NC. Bodoky G, et al. Invest New Drugs. 2012 Jun;30(3):1216-23. doi: 10.1007/s10637-011-9687-4. Epub 2011 May 19. Invest New Drugs. 2012. PMID: 21594619 Clinical Trial.
Cationic liposomal paclitaxel plus gemcitabine or gemcitabine alone in patients with advanced pancreatic cancer: a randomized controlled phase II trial.
Löhr JM, Haas SL, Bechstein WO, Bodoky G, Cwiertka K, Fischbach W, Fölsch UR, Jäger D, Osinsky D, Prausova J, Schmidt WE, Lutz MP; CT4001 Study Group. Löhr JM, et al. Among authors: bodoky g. Ann Oncol. 2012 May;23(5):1214-1222. doi: 10.1093/annonc/mdr379. Epub 2011 Sep 6. Ann Oncol. 2012. PMID: 21896540 Free article. Clinical Trial.
135 results